BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31617173)

  • 1. Engineering HSV-1 Vectors for Gene Therapy.
    Goins WF; Huang S; Hall B; Marzulli M; Cohen JB; Glorioso JC
    Methods Mol Biol; 2020; 2060():73-90. PubMed ID: 31617173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering HSV-1 vectors for gene therapy.
    Goins WF; Huang S; Cohen JB; Glorioso JC
    Methods Mol Biol; 2014; 1144():63-79. PubMed ID: 24671677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and production of recombinant herpes simplex virus vectors.
    Goins WF; Krisky DM; Wechuck JB; Huang S; Glorioso JC
    Methods Mol Biol; 2008; 433():97-113. PubMed ID: 18679619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
    Kahramanian A; Kuroda T; Wakimoto H
    Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of Herpes Simplex Virus Type 1 (HSV-1)-Based Amplicon Vectors.
    Fraefel C; Epstein AL
    Methods Mol Biol; 2020; 2060():91-109. PubMed ID: 31617174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
    Bommareddy PK; Peters C; Kaufman HL
    Methods Enzymol; 2020; 635():167-184. PubMed ID: 32122544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication-Competent Controlled Herpes Simplex Virus.
    Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
    J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and packaging of herpes simplex virus/adeno-associated virus (HSV/AAV) Hybrid amplicon vectors.
    Saydam O; Glauser DL; Fraefel C
    Cold Spring Harb Protoc; 2012 Mar; 2012(3):352-6. PubMed ID: 22383640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.
    Lilley CE; Groutsi F; Han Z; Palmer JA; Anderson PN; Latchman DS; Coffin RS
    J Virol; 2001 May; 75(9):4343-56. PubMed ID: 11287583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector.
    Huard J; Akkaraju G; Watkins SC; Pike-Cavalcoli M; Glorioso JC
    Hum Gene Ther; 1997 Mar; 8(4):439-52. PubMed ID: 9054519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes simplex virus clearance during purification of a recombinant adeno-associated virus serotype 1 vector.
    Ye GJ; Scotti MM; Thomas DL; Wang L; Knop DR; Chulay JD
    Hum Gene Ther Clin Dev; 2014 Dec; 25(4):212-7. PubMed ID: 25357151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication-defective genomic herpes simplex vectors: design and production.
    Burton EA; Bai Q; Goins WF; Glorioso JC
    Curr Opin Biotechnol; 2002 Oct; 13(5):424-8. PubMed ID: 12459332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene delivery using herpes simplex virus vectors.
    Burton EA; Fink DJ; Glorioso JC
    DNA Cell Biol; 2002 Dec; 21(12):915-36. PubMed ID: 12573050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.
    Heister T; Heid I; Ackermann M; Fraefel C
    J Virol; 2002 Jul; 76(14):7163-73. PubMed ID: 12072516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
    Grant KG; Krisky DM; Ataai MM; Glorioso JC
    Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of replication-competent and -defective HSV vectors.
    Goins WF; Krisky DM; Wechuck JB; Wolfe D; Huang S; Glorioso JC
    Cold Spring Harb Protoc; 2011 May; 2011(5):pdb.prot5615. PubMed ID: 21536761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy.
    Epstein AL; Marconi P; Argnani R; Manservigi R
    Curr Gene Ther; 2005 Oct; 5(5):445-58. PubMed ID: 16250886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.